Dengue
Conditions
Interventions
Patients will be classified as infected of healthy based on presenting symptoms. 100 patients presenting symptoms, will be allocated in the infected cohort will be monitored and blood samples will be
D20.215.894.899.162
Sponsors
Universidade Federal de Minas Gerais
Universidade Federal de Minas Gerais
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Eligibility
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Vaccination cohort: Participants between 18 to 90 years of age who agree to participate in the study. Absence of an acute clinical condition at the time of vaccination. Infected cohort: Participants under 18 yeas old. Participants with more than 5 days of symptoms. Participants who do not agree to sign the informed consent form. Participants who are not available to carry out the planned study visits
Exclusion criteria
Exclusion criteria: Vaccination cohort: Participants under 18 years old. Participants who are not available to carry out the planned visits of the study. Participants who do not agree to sign the informed consent form. Positive beta Human Chorionic Gonadotropin on the day of vaccination, in the case of women of reproductive potential. Participants who are pregnant or planning to become pregnant within the next 3 months after the last vaccine dose. Participants breastfeeding. Participant with a known or suspected immune system defect that may influence the immunological response to the vaccine, such as participants with congenital or acquired immunodeficiency, including human immunodeficientcy virus infection, post-organ transplant status or immunosuppressive therapy within 4 weeks prior to Visit 1. Therapy Immunosuppressive is defined as chronic administration of prednisone (more than 14 days) or equivalent more or equal than 2 miligramas por kilo por dia in the 4 weeks prior to study entry, radiotherapy or immunosuppressive cytotoxic drugs or monoclonal antibodies in the 3 previous years, topical and inhaled steroids are permitted. Infected cohort: Participants with more than 5 days of symptoms. Participants who do not agree to sign the Informed consent form. Participants who are not available to carry out the planned study visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detailed description of the immune response induced after vaccination and infection in young or elderly adult participants previously exposed or not to dengue. | — |
Secondary
| Measure | Time frame |
|---|---|
| Identification of immune factors (cellular or humoral immunity) associated with protection antiviral drugs induced after vaccination.;Identification of virus-specific B cell clones expanded and maintained after vaccination, and isolation of monoclonal antibodies with greater capacity to viral neutralization. | — |
Countries
Brazil
Contacts
Public ContactMauro Teixeira
Universidade Federal de Minas Gerais
Outcome results
None listed